Screening for Down syndrome using first-trimester combined screening followed by second-trimester ultrasound examination in an unselected population
| Autor: | François Vialard, Y Giudicelli, L. Malagrida, Patrick Rozenberg, Isabelle Lacroix, Sylvie Chevret, Isabelle Durand-Zaleski, Max Moulis, P. Boukobza, Yves Ville, Marc Roger, Marie Christine Jacquemot, Howard Cuckle, Jean-Pierre Bernard, Patrick Boccara, Jean Philippe Bault, Laurent Bidat, Chantal Chabry, Laurence Bussières |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Down syndrome medicine.medical_specialty Pregnancy-associated plasma protein A Aneuploidy Prenatal diagnosis Ultrasonography Prenatal Pregnancy Prenatal Diagnosis Prevalence Medicine Humans business.industry Obstetrics Ultrasound Obstetrics and Gynecology Health Care Costs medicine.disease Pregnancy Trimester First Pregnancy Trimester Second Gestation Female Down Syndrome business Trisomy |
| Zdroj: | American journal of obstetrics and gynecology. 195(5) |
| ISSN: | 1097-6868 |
| Popis: | Objective Recent studies have reported the efficacy of first-trimester combined screening for Down syndrome based on maternal age, serum markers (human chorionic gonadotropin, pregnancy-associated plasma protein A), and ultrasound measurement of fetal nuchal translucency. However, those do not incorporate the value of the widely accepted routine 20-22 weeks’ anomaly scan. Study design We carried out a multicenter, interventional study in the unselected population of a single health authority in order to assess the performance of first-trimester combined screening, followed by routine second trimester ultrasound examination and/or screening by maternal serum markers (free β-hCG and alpha-fetoprotein measurement or total hCG, alpha-fetoprotein, and unconjugated estriol measurement) when incidentally performed. Detection and screen positive rates were estimated using a correction method for nonverified issues. A cost analysis was also performed. Results During the study period, 14,934 women were included. Fifty-one cases of Down syndrome were observed, giving a prevalence of 3.4 per 1000 pregnancies. Of these, 46 were diagnosed through first (n = 41) or second (n = 5) trimester screening. Among the 5 screen-negative Down syndrome cases, all were diagnosed postnatally after an uneventful pregnancy. Detection and screen positive rates of first-trimester combined screening were 79.6% and 2.7%, respectively. These features reached 89.7%, and 4.2%, respectively, when combined with second-trimester ultrasound screening. The average cost of the full screening procedure was 108 € ($120) per woman and the cost per diagnosed Down syndrome pregnancy was 7,118 € ($7909). Conclusion Our findings suggest that 1 pragmatic interventional 2-step approach using first-trimester combined screening followed by second-trimester detailed ultrasound examination is a suitable and acceptable option for Down syndrome screening in pregnancy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect